83 related articles for article (PubMed ID: 37490258)
1. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
[TBL] [Abstract][Full Text] [Related]
2. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
[TBL] [Abstract][Full Text] [Related]
3. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Lyman GH; Kuderer NM; Aapro M
Front Oncol; 2021; 11():697908. PubMed ID: 34307165
[TBL] [Abstract][Full Text] [Related]
4. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis.
Dai HR; Yang Y; Wang CY; Chen YT; Cui YF; Li PJ; Chen J; Yang C; Jiao Z
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38760542
[TBL] [Abstract][Full Text] [Related]
5. Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics.
Li C; Preston RA; Dumas E; Beelen A; Marbury TC
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38639103
[TBL] [Abstract][Full Text] [Related]
6. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
Crawford J; Herndon D; Gmitter K; Weiss J
Future Oncol; 2024 Apr; ():. PubMed ID: 38587388
[TBL] [Abstract][Full Text] [Related]
7. Myelopreservation with Trilaciclib in recurrent advanced ovarian cancer: a case report.
Tan H; Han X; Li C; Liu W; Li K; Sheng X; Qi S
Front Oncol; 2024; 14():1343239. PubMed ID: 38764584
[TBL] [Abstract][Full Text] [Related]
8. Introduction to real-world evidence studies.
Chodankar D
Perspect Clin Res; 2021; 12(3):171-174. PubMed ID: 34386383
[No Abstract] [Full Text] [Related]
9. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.
Melosky BL; Leighl NB; Dawe D; Blais N; Wheatley-Price PF; Chu QS; Juergens RA; Ellis PM; Sun A; Schellenberg D; Ionescu DN; Cheema PK
Curr Oncol; 2023 Jun; 30(7):6289-6315. PubMed ID: 37504325
[TBL] [Abstract][Full Text] [Related]
10. Small Cell Lung Carcinoma: Current Diagnosis, Biomarkers, and Treatment Options with Future Perspectives.
Krpina K; Vranić S; Tomić K; Samaržija M; Batičić L
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509621
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance.
Kim J; Kim S; Park SY; Lee GK; Lim KY; Kim JY; Hwang JA; Yu N; Kang EH; Hwang M; Song BR; Park C; Han JY
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509231
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
[TBL] [Abstract][Full Text] [Related]
13. A rare case of combined small cell lung carcinoma with heterologous component of rhabdomyosarcoma diagnosed by endobronchial ultrasound (EBUS)-guided biopsy.
Cedano D; Cedano J; Fels Elliott DR; Assi J; Madan R; Hyter S; Pitts LR; Postigo Jasahui MR
Respir Med Case Rep; 2023; 45():101899. PubMed ID: 37521129
[TBL] [Abstract][Full Text] [Related]
14. Spatially Resolved Proteomic and Transcriptomic Profiling of Anaplastic Lymphoma Kinase-Rearranged Pulmonary Adenocarcinomas Reveals Key Players in Inter- and Intratumoral Heterogeneity.
Szeitz B; Glasz T; Herold Z; Tóth G; Balbisi M; Fillinger J; Horváth S; Mohácsi R; Kwon HJ; Moldvay J; Turiák L; Szász AM
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511126
[TBL] [Abstract][Full Text] [Related]
15. The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
Igawa S; Yamamoto H; Yamada K; Akazawa Y; Manaka H; Yagami Y; Nakahara Y; Sato T; Mitsufuji H; Sasaki J; Naoki K
Oncology; 2023; 101(11):695-704. PubMed ID: 37494886
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of platinum-induced peripheral neuropathy in cancer patients].
Chubykina SV; Tatarinova MY; Avakyan GG
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7):19-24. PubMed ID: 37490661
[TBL] [Abstract][Full Text] [Related]
17. Proteomic Analysis Reveals Trilaciclib-Induced Senescence.
Hermosilla-Trespaderne M; Hu-Yang MX; Dannoura A; Frey AM; George AL; Trost M; Marín-Rubio JL
Mol Cell Proteomics; 2024 Apr; 23(6):100778. PubMed ID: 38679389
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
